InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to Conduct Key Research with TransBIOTech, Names New COO
April 22, 2022

InvestorNewsBreaks — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to Conduct Key Research with TransBIOTech, Names New COO

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to establish a foundation for further research focused on specific understandings of the company’s recent chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. In addition, AREV also named a new chief operating officer. The company noted that Kevin Phelps, CPA and AREV board member, will be assuming the responsibilities of company COO. Phelps brings 40 years of biotech and general business expertise to the new role. He has served in a variety of executive positions, including as CEO, CFO and vice president of business development.

“TransBIOTech is engaging with AREV in its initial research on cannabinoids and other early-stage commercial research programs,” said AREV CEO Mike Withrow in the press release. “Our agreement with TransBIOTech signals the initiation of a robust clinical initiative with numerous collaborators to facilitate data on some of the more promising phytomedicinal therapeutics currently relevant to today’s public health challenges. AREV Life Sciences is determined to enhance our scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovation relevant to contemporary pandemic infectious disease and human nutrition. By leveraging our proprietary extraction technologies paired with the discovery capacities of TransBIOTech and other well-respected research institutions, we are laying the groundwork for initial animal studies to identify data sets that will satisfy regulatory authorities.”

To view the full press releases, visit https://ibn.fm/0O6T0 and https://ibn.fm/in57L

ABOUT AREV Life Sciences Global Corp. 

AREV Life Sciences Global is a publicly traded, fully integrated, early-stage life science enterprise with a U.S. subsidiary dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and elevated inflammatory responses. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic comorbidities and innovations in human nutrition. In addition to its phytomedicinal discovery program, AREV is developing a next-generation Ready-to-Use Therapeutic Food (“RUTF”). SUSTAINN is designed by AREV in collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba that demonstrates clinical attributes addressing serious acute malnutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and the Biotechnology Innovation Organization. For more information about the company, please visit www.AREVLifeSciences.com

NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).